shr-1905
mAbexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Jul 27, 2021 (NCT04800263)
Timeline
Indications
Mechanism of action
- LymphocytesINHIBITOR
Lymphocytes inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07211542 | Phase 2 | Nov 30, 2025 | Hengrui Therapeutics, Inc. |
| NCT07098403 | Phase 3 | Sep 3, 2025 | Hengrui Therapeutics, Inc. |
| NCT07132827 | Phase 3 | Aug 28, 2025 | Hengrui Therapeutics, Inc. |
| NCT06748053 | Phase 2 | Feb 13, 2025 | GlaxoSmithKline |
| NCT06786455 | Phase 2 | Jan 23, 2025 | Hengrui Therapeutics, Inc. |
| NCT05891483 | Phase 2 | Sep 4, 2023 | Hengrui Therapeutics, Inc. |
| NCT05593250 | Phase 2 | Oct 25, 2022 | Hengrui Therapeutics, Inc. |
| NCT04800263 | Phase 1 | Jul 27, 2021 | Atridia Pty Ltd. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 6 | 6 | 2 | 2022 |
| Atridia Pty Ltd. | For profit | 1 | 1 | 1 | 2021 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1